Introduction {#S0001}
============

*Escherichia coli* is a member of Enterobacteriaceae, and it is an important opportunistic pathogen. *E. coli* is the leading cause of urinary tract infections and the cause of a variety of other infections, including liver abscesses and bacteremia. *E. coli* that carry extended-spectrum β-lactamase (ESBL) are very common.[@CIT0001] Besides tigecycline and colistin, carbapenems are often the last resort for treating infections due to ESBL-producing *E. coli*. However, the emergence of carbapenemase has contributed to resistance to all β-lactams including carbapenems. New Delhi metallo-beta-lactamase (NDM) is one of the most important carbapenemases. Since the first report of *bla*~NDM-1~ in 2009,[@CIT0002] 24 NDM variants (NDM-1 to NDM-24) were identified.[@CIT0003] NDM spread among Enterobacteriaceae and other Gram-negative bacteria, such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*,[@CIT0004],[@CIT0005] and *E. coli* is the predominant carrier of *bla*~NDM~.

NDM-7 differs from NDM-1 by the substitution of two amino acids at positions 130 (Asp→Asn) and 154 (Met→Leu). NDM-7 was first described in an *E. coli* strain in Germany in 2013, and it exhibited higher carbapenemase activity compared to NDM-1.[@CIT0006] NDM-7 was reported sporadically in many countries.[@CIT0007]--[@CIT0013] NDM-7-producing *E. coli* was first reported in 2016 in China. *bla*~NDM-7~ was located on a conjugative IncX3-type plasmid in five clinically isolated *E. coli* strains of sequence types ST131 and ST650 in the Jiangxi Province.[@CIT0014] Yingying Hao et al recently reported an NDM-7-producing *E. coli* ST167 strain isolated from a urine sample in the Shandong Province of China, and *bla*~NDM-7~ was also located on a conjugative IncX3-type plasmid.[@CIT0015] IncX3-type plasmids likely play an important role in the distribution of *bla*~NDM-7~ in China. Considering the global emergence of NDM-7, an epidemiological survey and analysis of *bla*~NDM-7~-harboring strains are urgently needed to prevent its future prevalence.

The present study isolated an NDM-7-producing *E. coli* strain from a male patient hospitalized in a tertiary hospital in the Zhejiang Province of China. The entire genome of the strain was sequenced, and the *bla*~NDM-7~-harboring plasmid was analyzed. Genomic characterization and molecular epidemiology of the strain were further elucidated.

Material and methods {#S0002}
====================

Patient and isolate {#S0002-S2001}
-------------------

A 57-year-old male patient diagnosed with pulmonary infection was hospitalized in a tertiary hospital in the Zhejiang Province of China on August 14, 2017. The patient had a pulmonary infection and comorbidities, including hypoxic-ischemic encephalopathy, hypertension, and hypertensive heart disease. During his hospitalization, the patient received an indwelling urinary catheter. Routine urine tests suggested a urinary tract infection, and carbapenem-resistant *E. coli* was isolated from a urine sample on August 17, 2017. The strain was preliminarily identified using the VITEK MS system (bioMérieux, France) and further confirmed using 16S rRNA gene sequencing.

Antimicrobial susceptibility test {#S0002-S2002}
---------------------------------

A susceptibility assay to antibiotics was performed according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The minimum inhibitory concentrations (MICs) of tigecycline and colistin (Sigma-Aldrich, St. Louis, MO, USA) were determined using standard broth microdilution tests with fresh Mueller-Hinton broth (Cation-adjusted, Oxoid LTD, England). The MICs of other antimicrobial agents were determined using the Etest method. Antimicrobial susceptibility was determined using the breakpoints approved by the CLSI, and the US Food and Drug Administration (FDA) breakpoints were used for tigecycline.

Whole-genome sequencing {#S0002-S2003}
-----------------------

Genomic DNA of the isolate was extracted using a QIAamp DNA MiniKit (Qiagen, USA) and subjected to whole-genome sequencing (WGS) using the Illumina HiSeqTM 4000 platform (Illumina, San Diego, CA, USA). The short reads generated were *de novo* assembled into contigs using SPAdes. To obtain the complete sequence, EC25 was subjected to sequencing using the long-read MinION Sequencer (Nanopore, Oxford, UK). The MinION sequencing libraries were prepared using the rapid barcoding kit and loaded onto a single MinION R9.4 flow cell. The MinION reads were base-called with Albacore v2.0.2 and generated 2.4 Gbp of data. Raw and trimmed Illumina reads were assessed using FastQC v0.11.7, and quality trimming was performed using Trimmomatic v0.32. The MinION reads were demultiplexed and quality-trimmed using Porechop v0.2.3 with the default settings. The *de novo* hybrid assembly of short Illumina reads and long MinION reads was performed using Unicycler (v0.4.7; parameters: -min_component_size 500-min_dead_end_size 500-verbosity 1-mode conservative) under conservative mode for increased accuracy. Complete circular contigs generated were corrected using Pilon with Illumina reads for several rounds until no change was detected. We obtained one circular contig, which was represented by a complete chromosome with a size of 4,782,653 bp and five plasmids of 227,349 bp, 46,161 bp, 5,167 bp, 4,991 bp, and 3,373 bp. The whole-genome sequence was annotated in the NCBI Prokaryotic Genomes Annotation Pipeline (PGAP) server.

Identification of antimicrobial resistance genes {#S0002-S2004}
------------------------------------------------

Acquired antimicrobial resistance genes were identified using ResFinder 3.0 with a 99% threshold for gene identification and a 100% minimum length via depositing of the entire genome sequence into the database.[@CIT0016] The carbapenem-resistant gene *bla*~NDM-7~ was confirmed using PCR and Sanger sequencing.

Genomic characterization {#S0002-S2005}
------------------------

Multilocus sequence typing (MLST) of the isolate was analyzed using the BacWGSTdb server of the entire genome sequence.[@CIT0017] Virulence genes and plasmid replicon type were analyzed using VirulenceFinder 1.5 and PlasmidFinder 1.3.[@CIT0016] Further bioinformatics analysis, such as identification of insertion elements (IS), clustered regularly interspaced short palindromic repeat (CRISPR) sequences and secondary metabolite gene clusters, were predicted using applications of ISfinder, CRISPRFinder, and antiSMASH tools, respectively.[@CIT0018],[@CIT0019]

Plasmid analysis {#S0002-S2006}
----------------

The plasmid sequences were annotated in the NCBI Prokaryotic Genomes Annotation Pipeline (PGAP) server. A graphical map of the *bla*~NDM-7~-carrying plasmid was converted in the CGView Server and completed with labels and footnotes.[@CIT0020]

Phylogenetic relationship analysis {#S0002-S2007}
----------------------------------

The phylogenetic relationship between EC25 and other *E. coli* strains was analyzed using the BacWGSTdb server and the entire genome sequence.[@CIT0017] The BacWGSTdb server offers SNP and genome MLST approaches to investigate the phylogenetic relationship of the uploaded genome sequence with sequences deposited in the BacWGSTdb. The database currently contains 10,545 *E. coli* strains, including 77 strains of ST410. Scheme cgMLST was used with a 200 threshold for phylogenetic analysis.

Nucleotide sequence accession numbers {#S0002-S2008}
-------------------------------------

The complete sequence of strain *E. coli* EC25 and plasmids were submitted to GenBank under accession number CP035123-CP035128.

Ethical approval {#S0002-S2009}
----------------

The urine sample and clinical isolate of *E. coli* EC25 were generated as part of routine hospital laboratory procedures. This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Zhejiang Provincial People's Hospital, China. Written informed consent was obtained from the patient, which included publication of the case details.

Results and discussion {#S0003}
======================

The MICs of strain EC25 to different antibiotics are presented in [Table 1](#T0001){ref-type="table"}. The strain was resistant to all antimicrobials tested except tigecycline and colistin.Table 1MICs of the antibiotics tested in *E. coli* EC25AntibioticsMIC(mg/L)Cefazolin^a^\>256Ceftriaxone^a^\>256Cefotaxime^a^\>256Cefepime^a^\>256Imipenem^a^\>32Meropenem^a^\>32Aztreonam^a^\>32Amoxicillin/clavulanate^a^\>256Cefoperazone/sulbactam^a^\>256Ciprofloxacin^a^\>32Gentamicin^a^\>256Tetracycline^a^\>256Tigecycline^b^0.25Colistin^b^0.25[^1]

The whole-genome sequence of *E. coli* EC25 was composed of one chromosomal DNA that comprised 4,782,653 bp and five plasmids of 227,349 bp, 46,161 bp, 5,167 bp, 4,991 bp, and 3,373 bp. The chromosomal DNA contained 88 tRNA genes, 3 rRNA operons, and 4,707 protein-coding sequences, which were identified using the PGAP server. The MLST scheme revealed that EC25 belonged to sequence type ST410. The genome contained two confirmed CRISPRs (CRISPR1 start position and end position: 1,042,955--1,043,471, CRISPR length: 516; CRISPR2 start position and end position: 1,065,855--1,066,433, CRISPR length: 578). Several IS elements were found in the genome, and most belonged to the IS*3* and IS*5* families. Four secondary metabolite regions, nrps-t1pks, thiopeptide, NRPS, and siderophore, were also identified.

Four virulence factors were found in the genome ([Table 2](#T0002){ref-type="table"}), which were two copies of *gad* (glutamate decarboxylase), a single copy of *iss* (increased serum survival) and *lpfA* (long polar fimbriae). The distribution of the resistance genes in the genome of the strain EC25 is presented in [Table 3](#T0003){ref-type="table"}. We identified the aminoglycoside resistance genes *aph(3ʹʹ)-Ib, aph(6)-Id, aac(3)-IId, aadA16, aac(6ʹ)-Ib-cr,* and *aadA5*, the beta-lactam resistance genes *bla*~NDM-7~, *bla*~OXA-1~, *bla*~TEM-1B~, and *bla*~CTX-M-3~, the fluoroquinolone resistance genes *qnrB2, aac(6ʹ)Ib-cr* and *qnrS1*, the rifampicin resistance gene *arr-3*, the macrolide, lincosamide and streptogramin B resistance gene *mph(A)*, the sulfonamide resistance genes *sul1*and *sul2*, the tetracycline resistance gene *tet(A)*, and the trimethoprim resistance genes *dfrA27* and *dfrA17*. Except for *bla*~NDM-7~, all of the resistance genes were located in the IncF-type plasmid pEC25-1, including two copies of *aac(6ʹ)Ib-cr* and *mph(A)* and three copies of *sul1*. The carbapenem-resistant gene *bla*~NDM-7~ was located in an individual plasmid, pEC25_NDM-7.Table 2Virulence genes in strain *E. coli* EC25Virulence factorIdentityQuery/template lengthContigPosition in contigProtein functionAccession numbergad1001401/1401EC25251,983..253,383Glutamate decarboxylaseAP010953gad99.791401/1401EC252,444,792..2,446,192Glutamate decarboxylaseCP002967iss98.64294/294EC253,714,038..3,714,331Increased serum survivalCP004009lpfA100573/573EC254,749,714..4,750,286Long polar fimbriaeAY646923 Table 3Distribution of resistance genes in *E. coli* strain EC25Resistance gene%identityHSP length/queryContigPosition in contigPredicted phenotypeAccession numberAminoglycoside*aph(3ʹ')-Ib*100804/804pEC25-194,244..95,047Aminoglycoside resistanceAF321551*aph(6)-Id*100837/837pEC25-195,047..95,883Aminoglycoside resistanceM28829*aac(3)-IId*99.88861/861pEC25-197,435..98,295Aminoglycoside resistanceEU022314*aadA16*99.65846/846pEC25-1111,488..112,333Aminoglycoside resistanceEU675686*aac(6ʹ)-Ib-cr*100600/600pEC25-1113,669..114,268Fluoroquinolone and aminoglycoside resistanceDQ303918*aadA5*100789/789pEC25-1204,055.204,843Aminoglycoside resistanceAF137361*aac(6ʹ)-Ib-cr*100600/600pEC25-1208,288.208,887Fluoroquinolone and aminoglycoside resistanceDQ303918Beta-lactam*bla*~NDM-7~100813/813pEC25_NDM-744,052..44,864Beta-lactam resistanceJX262694*bla*~OXA-1~100831/831pEC25-1209,018..209,848Beta-lactam resistanceHQ170510*bla*~TEM-1B~100861/861pEC25-1214,606.215,466Beta-lactam resistanceAY458016*bla*~CTX-M-3~100876/876pEC25-1216,248..217,123Beta-lactam resistanceY10278Fluoroquinolone*qnrB2*99.84645/645pEC25-1105,800..106,444Fluoroquinolone resistanceDQ351242*aac(6ʹ)-Ib-cr*100600/600pEC25-1113,669..114,268Fluoroquinolone and aminoglycoside resistanceDQ303918*aac(6ʹ)-Ib-cr*100600/600pEC25-1208,288..208,887Fluoroquinolone and aminoglycoside resistanceDQ303918*qnrS1*100657/657pEC25-1221,088..221,744Fluoroquinolone resistanceAB187515Rifampicin*arr-3*100453/453pEC25-1113,120..113,572Rifampicin resistanceJF806499MLS - Macrolide, Lincosamide and Streptogramin B*mph(A)*100906/906pEC25-199,354..100,259Macrolide resistanceD16251*mph(A)*100906/906pEC25-1196,453..197,358Macrolide resistanceD16251Sulphonamide*sul2*100816/816pEC25-193,368..94,183Sulphonamide resistanceHQ840942*sul1*100840/840pEC25-1104,470..105,309Sulphonamide resistanceU12338*sul1*100840/840pEC25-1110,191..111,030Sulphonamide resistanceU12338*sul1*100840/840pEC25-1202,669..203,508Sulphonamide resistanceU12338Tetracycline*tet(A)*1001200/1200pEC25-1118,110..119,309Tetracycline resistanceAJ517790Trimethoprim*dfrA27*100474/474pEC25-1112,514..112,987Trimethoprim resistanceFJ459817*dfrA17*100474/474pEC25-1204,974..205,447Trimethoprim resistanceFJ460238

The plasmid profile of pEC25_NDM-7 is presented in [Figure 1](#F0001){ref-type="fig"}. It is an IncX3-type plasmid composed of 46,161 bp. The carbapenem-resistant gene *bla*~NDM-7~ was preceded by Tn3-IS3000-IS30-IS5 in the upstream region and followed by *ble*~MBL~-*trp*F-*dsb*C-*cut*A-IS26 in the downstream region. The similarity of pEC25_NDM-7 to other *bla*~NDM~-harboring plasmids was analyzed using Basic Local Alignment Search Tool (BLAST). pEC25_NDM-7 was 99% identical to several previously reported plasmids, namely, pJN05NDM7 (Accession No. MH523639), pAD-19R (Accession No. KX833071), pNDM-20 (Accession No. MF458176), pM216_X3 (Accession No. AP018146), and pKW53T-NDM (Accession No. KX214669). Plasmid pJN05NDM7 (carrying *bla*~NDM-7~) was identified in an *E. coli* ST167 clinical strain isolated from a patient with a urinary tract infection at a teaching hospital in the Shandong Province of China in 2015.[@CIT0015] Plasmid pAD-19R (carrying *bla*~NDM-17~) was identified in an *E. coli* ST48 strain isolated from a chicken at a commercial poultry farm in the Shandong Province of China in 2015.[@CIT0021] Plasmid pNDM-20 (carrying *bla*~NDM-20~) was identified in an *E. coli* ST1114 strain isolated from a swine faecal swab collected from a commercial pig farm in the Shandong province of China in 2016.[@CIT0022] Plasmid pM216_X3 (carrying *bla*~NDM-4~) was identified in an *E. coli* ST101 clinical strain isolated from a urine specimen at a tertiary care hospital in Yangon, Myanmar, in 2015.[@CIT0023] Plasmid pKW53T-NDM (carrying *bla*~NDM-7~) was identified in an *E. coli* ST448 clinical strain isolated from a urine sample in Kuwait in 2012.[@CIT0012] These plasmids encode distinct *bla*~NDM~ variants, and it is likely that *bla*~NDM~ mutates from *bla*~NDM-1~ to other *bla*~NDM~ variants via nucleic acid replication in the 46,161 bp IncX3-type plasmid to evolve higher carbapenemase activity. Notably, the 46,161 bp IncX3-type plasmid does not carry antimicrobial resistance genes other than *bla*~NDM~, and the plasmid appeared in different ST type of *E. coli* strain across different countries in humans and animals. It seems the structure of the 46,161 bp plasmid is stable and suitable for the horizontal transfer of *bla*~NDM~, which plays an important role in horizontal transmission of NDM carbapenemase worldwide.Figure 1Profile of the *bla*~NDM-7~-encoding plasmid pEC25_NDM-7.

The phylogenetic relationship between *E. coli* EC25 and other *E. coli* strains is presented in [Table 4](#T0004){ref-type="table"} and [Figure 2](#F0002){ref-type="fig"}. Twenty-one phylogenetically related strains were identified in the database, all of which belong to ST410. Most of these strains produce ESBL, and only six strains produced carbapenemase, including one KPC-2-producing strain, one VIM-4-producing strain, and four NDM-producing strains. The phylogenetically related *E. coli* ST410 strains are spread globally. Seven strains were isolated from Germany, five strains from the USA, four strains from China, two strains from Norway, and one strain each from Argentina, Brazil, and India. Of the four strains from China, two of the strains were isolated from the Zhejiang province, one strain was from the Jiangsu province, and one strain was from the Sichuan province. The strain closest to EC25 was *E. coli* SCEC020001, which was isolated from the Sichuan province of China in 2016. There are only 38 different alleles between *E. coli* EC25 and *E. coli* SCEC020001. *E. coli* SCEC020001 also harbors a 46,161 bp IncX3-type plasmid (pNDM5_020001, Accession No. CP032424) that encodes *bla*~NDM-5~. pNDM5_020001 was 99% identical to pEC25_NDM-7. The main difference between the two plasmids was the subtype of *bla*~NDM~; pNDM5_020001 encoded *bla*~NDM-5~ and pEC25_NDM-7 encoded *bla*~NDM-7~. There is a geographic distinction between the Zhejiang province and Sichuan province, and the patient did not have a travel history out of Zhejiang province in recent years, which suggests that the NDM-positive *E. coli* ST410 strain EC25 was locally acquired, and the *bla*~NDM-7~ subtype may evolve during local dissemination.Table 4Information of close isolates (based on cgMLST strategy) to strain *E. coli* EC25IsolateAccession numberSTHostIsolation sourceCountry stateCollection yearMajor resistance genotypeDifferent allelesReferenceEC25CP035123410Homo sapiensUrineChina: Zhejiang2017*bla*~NDM-7~0This studySCEC020001CP032426410Homo sapiensN/A^a^China: Sichuan2016*bla*~NDM-5~38UnpublishedIMT31352LJGF01410DogFecesGermany2013ESBL96[@CIT0025]IMT28764LJGC01410Mute swanFecesGermany2012ESBL97[@CIT0025]IMT33180LJGI01410Homo sapiensBloodGermany2009ESBL99[@CIT0025]IMT28707LJGB01410Mute swanFecesGermany2012ESBL99[@CIT0025]IMT33204LJGK01410Homo sapiensBloodGermany2010ESBL103[@CIT0025]IMT33181LJGJ01410Homo sapiensBloodGermany2009ESBL118[@CIT0025]Ecol_517CP018965410Homo sapiensN/A^a^Brazil:2011*bla*~KPC-2~119[@CIT0026]UCI_53JMVS01410Homo sapiensBiliary drainUSA2013ESBL127[@CIT0027]Swine70LVOT01410SusscrofaRectumChina: Jiangsu2012- ^b^135UnpublishedYD786CP013112410Homo sapiensUrineUSA2012ESBL138[@CIT0028]CoR-20MKFO01410Homo sapiensSputumChina: Zhejiang2014ESBL145UnpublishedAST_82LLXC01410N/A^a^N/A^a^USA2015AmpC147Unpublished979PIJB01410Homo sapiensUrineArgentina2016ESBL150UnpublishedCoR-35NISA01410Homo sapiensAscitesChina: Zhejiang2015ESBL153UnpublishedK71-77LNGY01410Homo sapiensBloodNorway2010*bla*~NDM-1~164[@CIT0029]RL465FLKU01410N/A^a^N/A^a^GermanyN/A^a^ESBL174[@CIT0030]AR434CP029122410N/A^a^N/A^a^USAN/A^a^- ^b^176Unpublished50,822,286LNIK01410Homo sapiensRectal swabNorway2014*bla*~VIM-4~185[@CIT0031]908,555AXTR01410Homo sapiensN/A^a^USAN/A^a^- ^b^193UnpublishedBV643PVPJ01410Homo sapiensBloodIndia2016*bla*~NDM-5~194Unpublished[^2] Figure 2Phylogenetic relationship between *E. coli* ST410 strain EC25 and other *E. coli* strains. Twenty-one phylogenetically related strains were identified in the BacWGSTdb server. All of these strains belonged to ST410. Seven strains were isolated from Germany, five from the USA, four from China, two from Norway, and one each from Argentina, Brazil, and India.

A variety of STs were found in NDM-positive *E. coli* strains worldwide, and there are no predominant STs. The number of large-scale studies examining the clonal background of NDM-positive *E. coli* strains is limited in China. Zhang R et al suggested that ST167 and ST410 were two of the most common sequence types of NDM-positive *E. coli* strains in China.[@CIT0024] We report the whole-genome sequence of a clinically isolated *E. coli* ST410 strain harboring *bla*~NDM-7.~ Our study is the first report on fully sequenced *E. coli* ST410 strain carrying *bla*~NDM-7~ isolated from China because *bla*~NDM-7~ is rare. A similar NDM-positive *E. coli* ST410 strain was found in the BacWGSTdb server in other provinces of China. ST410 is more likely to emerge as a successful epidemic clone of NDM-producing *E. coli* in China, and the *bla*~NDM~ gene is prone to mutate during its dissemination. Therefore, more studies are required to illuminate the epidemic clones of NDM-positive *E. coli* in China.

Conclusion {#S0004}
==========

In summary, our study reports the first identification of a clinical carbapenem-resistant *E. coli* ST410 strain carrying *bla*~NDM-7~ recovered from a urinary tract infection in China. Our study highlights the potential transmission opportunity of carbapenem-resistant plasmid carriage in *E. coli*. Further studies involving more NDM-producing isolates are warranted to identify reservoirs and monitor the transmission dynamics of *bla*~NDM~ genes in China.
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[^1]: **Notes:** ^a^Tested by Etest method. ^b^Tested by standard broth microdilution tests.

[^2]: **Notes:** ^a^Data not available. ^b^No carbapenemase, ESBL, and AmpC-type ß-Lactamases can be found in the genome.
